Founder H Fund

The firm does not publish a named investment committee or principal roster on its corporate website. As a wholly owned subsidiary of Founder Securities, key investment and operational oversight lines run to the parent's PE division, which is regulated by the China Securities Regulatory Commission.

The healthcare strategy operates through two disclosed onshore funds: a $100 million growth-stage vehicle targeting medical services, devices, IT, and pharmaceuticals, and a RMB 300 million early-stage fund focused on precision medicine, medical devices, drug R&D, and healthcare services (per the firm).

Except for the $100 million healthcare growth fund, which is USD-denominated but remains onshore in structure, the firm's three other disclosed vehicles — RMB 300 million, RMB 1 billion, and RMB 5 billion — are all RMB-denominated. No offshore or Cayman-domiciled funds are listed.

Founder H Fund sits under Founder Securities, which is majority-owned by the Peking University Founder Group. The parent conglomerate was founded in 1986 as a Peking University enterprise and underwent a court-administered restructuring in 2020, emerging in 2021 under a consortium led by Ping An Insurance and a Zhuhai state-owned entity. The firm’s capital base and regulatory posture remain tied to this restructured parent.

The firm's four main vehicles span seed to pre-IPO. The early-stage RMB 300 million and RMB 1 billion funds target seed and startup rounds, while the RMB 5 billion tech growth fund and $100 million healthcare growth fund pursue expansion, late-stage, and pre-IPO deals. PIPE investments and fund-of-funds commitments are also within the disclosed mandate (per the firm).